Pacer Advisors
TPTX

Pacer Advisors’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Pacer Advisors’s Portfolio TPTX Stock Details TPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-678
Closed -$64K – 1599
2021
Q1 		$64K Sell
678
-433
-39% -$51.5K ﹤0.01% 1407
2020
Q4 		$135K Hold
1,111
– – ﹤0.01% 1309
2020
Q3 		$97K Buy
+1,111
New +$77.4K ﹤0.01% 1253

Other funds holding TPTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Pacer Advisors's TPTX Position: Q2 2021 in Review

Pacer Advisors sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q2 2021, closing a stake of 678 shares — an estimated $64K sold.

Pacer Advisors first reported a position in TPTX in Q3 2020 and held it in 3 quarters. The position peaked at $135K in Q4 2020. 190 funds tracked by Wall St. Rank hold TPTX as of Q2 2021.

  • Pacer Advisors reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • Pacer Advisors sold 678 Turning Point Therapeutics, Inc. Common Stock shares in Q2 2021, an estimated $64K.
  • Pacer Advisors first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q3 2020 and held it in 3 quarters.
  • Pacer Advisors's Turning Point Therapeutics, Inc. Common Stock position peaked at $135K in Q4 2020.
  • 190 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q2 2021.

Based on Pacer Advisors's 13F filing for Q2 2021, filed 21 Jul 2021.